Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Colombia | India
Approved Indications: None
Known Adverse Events: None
Company: Aesculap
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Glaucoma|Intestinal Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
202011030DIPB | N/A |
Recruiting |
Pituitary Diseases|Spinal Diseases|Cerebrospinal Fluid Leak |
2025-12-31 |
|
H-37652 | N/A |
Withdrawn |
Colic |
2022-06-01 |
|
NCT03510143 | N/A |
Unknown status |
Thoracic Cancer|Thyroid Cancer |
2020-05-01 |
|
1PN1010510 | P4 |
Completed |
Glaucoma |
2006-05-01 |